Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at codrituzumab for advanced liver cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at a drug called codrituzumab which was previously known as GC33.
It was for people with a type of liver cancer called hepatocellular cancer (HCC) that had spread to other parts of the body (advanced cancer).
HCC is the most common type of liver cancer.
More about this trial
This trial started in 2012 and these results were published in 2016. Researchers wanted to find out whether codrituzumab helped people with advanced hepatocellular cancer and how safe it was.
Codrituzumab is a type of targeted drug called a monoclonal antibody. It seeks out cancer cells by looking for particular proteins.
Everyone who took part had either codrituzumab or a dummy drug (
Summary of results
- 125 people had codrituzumab
- 60 people had a dummy drug
- almost 3 months for people in the codrituzumab group
- almost 2 months for people in the dummy drug group
- people who had codrituzumab lived about 9 months after treatment
- people who had the dummy drug lived around 10 months after treatment
The trial team looked at the most common side effects of codrituzumab. They were:
- high temperature (fever)
- tiredness (fatigue)
- feeling or being sick
- decrease appetite
- diarrhoea or constipation
- a build up of fluid (oedema) and itchy skin
- pain in the tummy (abdomen) and headaches
The trial team concluded that the side effects of codrituzumab are acceptable. But the trial team could not show, in a statistical way, that codrituzumab helps people with advanced hepatocellular cancer. They formulated different theories for this and might look at different doses of codrituzumab in the future.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Experimental Cancer Medicine Centre (ECMC)